Saravolac EG[au] - Search Results

Year	Number of Results
1991	1
1994	1
1995	1
1996	2
1997	1
1999	2
2000	2
2001	1
2002	2
2007	2
2010	2
2024	0

1

Saravolac EG, Wong JP, Cairns MJ. Saravolac EG, et al. Recent Pat Antiinfect Drug Discov. 2010 Jan;5(1):44-57. doi: 10.2174/157489110790112590. Recent Pat Antiinfect Drug Discov. 2010. PMID: 19807677 Review.

2

Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza.

Wong JP, Christopher ME, Salazar AM, Sun LQ, Viswanathan S, Wang M, Saravolac EG, Cairns MJ. Wong JP, et al. Among authors: saravolac eg. Front Biosci (Schol Ed). 2010 Jan 1;2(2):791-800. doi: 10.2741/s102. Front Biosci (Schol Ed). 2010. PMID: 20036985 Free article. Review.

3

Catalytic nucleic acids: from lab to applications.

Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Sun LQ, et al. Among authors: saravolac eg. Pharmacol Rev. 2000 Sep;52(3):325-47. Pharmacol Rev. 2000. PMID: 10977866 Review.

4

Catalytic DNA: a novel tool for gene suppression.

Cairns MJ, Saravolac EG, Sun LQ. Cairns MJ, et al. Among authors: saravolac eg. Curr Drug Targets. 2002 Jun;3(3):269-79. doi: 10.2174/1389450023347722. Curr Drug Targets. 2002. PMID: 12041740 Review.

5

Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM. Bhindi R, et al. Among authors: saravolac eg. Am J Pathol. 2007 Oct;171(4):1079-88. doi: 10.2353/ajpath.2007.070120. Epub 2007 Aug 23. Am J Pathol. 2007. PMID: 17717148 Free PMC article. Review.

6

Recent Patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections.

Saravolac EG, Wong JP. Saravolac EG, et al. Recent Pat Antiinfect Drug Discov. 2007 Jun;2(2):140-7. doi: 10.2174/157489107780832622. Recent Pat Antiinfect Drug Discov. 2007. PMID: 18221170 Review.

7

Cellular uptake, distribution, and stability of 10-23 deoxyribozymes.

Dass CR, Saravolac EG, Li Y, Sun LQ. Dass CR, et al. Among authors: saravolac eg. Antisense Nucleic Acid Drug Dev. 2002 Oct;12(5):289-99. doi: 10.1089/108729002761381276. Antisense Nucleic Acid Drug Dev. 2002. PMID: 12477279

8

Cationic lipid-mediated transfection of cells in culture requires mitotic activity.

Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB. Mortimer I, et al. Among authors: saravolac eg. Gene Ther. 1999 Mar;6(3):403-11. doi: 10.1038/sj.gt.3300837. Gene Ther. 1999. PMID: 10435090

9

Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties.

Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, Clow K, Leng E, Sun R, Cullis PR, Scherrer P. Zhang YP, et al. Among authors: saravolac eg. Gene Ther. 1999 Aug;6(8):1438-47. doi: 10.1038/sj.gt.3300965. Gene Ther. 1999. PMID: 10467368

10

Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity.

Saravolac EG, Ludkovski O, Skirrow R, Ossanlou M, Zhang YP, Giesbrecht C, Thompson J, Thomas S, Stark H, Cullis PR, Scherrer P. Saravolac EG, et al. J Drug Target. 2000;7(6):423-37. doi: 10.3109/10611860009102217. J Drug Target. 2000. PMID: 10758913

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year